Loading…

P750Role of circulating endothelial cells post-heart transplantation

Abstract Background The role of endothelial progenitor cells (EPC) in heart transplantation (HT) is not well defined. Thus, the aim of this study was to evaluate prospectively the dynamic changes of circulating EPC levels in relation to post-HT rejection risk. Methods There were 27 HT recipients who...

Full description

Saved in:
Bibliographic Details
Published in:European heart journal 2019-10, Vol.40 (Supplement_1)
Main Authors: Rywik, T, Braniewska, A, Kowalik, I, Firczuk, M, Kozar-Kaminska, K, Wojciechowska, A, Kasprzyk-Pawelec, A, Sobieszczanska-Malek, M, Leszek, P, Rozentryt, P, Zielinski, T
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue Supplement_1
container_start_page
container_title European heart journal
container_volume 40
creator Rywik, T
Braniewska, A
Kowalik, I
Firczuk, M
Kozar-Kaminska, K
Wojciechowska, A
Kasprzyk-Pawelec, A
Sobieszczanska-Malek, M
Leszek, P
Rozentryt, P
Zielinski, T
description Abstract Background The role of endothelial progenitor cells (EPC) in heart transplantation (HT) is not well defined. Thus, the aim of this study was to evaluate prospectively the dynamic changes of circulating EPC levels in relation to post-HT rejection risk. Methods There were 27 HT recipients who had EPC from peripheral blood quantified during 6 months follow-up after HT. Patients were monitored regularly, by right ventricular endomyocardial biopsy assessment, for cellular rejection (ACR) defined as grade ≥2 or an antibody-mediated rejection (AMR) characterized by histopathological changes recorded as AMR1H. The primary end-point was acute rejection, either AMR or ACR. Results ACR and AMR were observed in 7 (25.9%) and 6 (22.2%) subjects respectively. EPC levels, after logarithmic transformation, immediately post-HT were alike regardless of ACR status, however patients with lower EPC were at risk of AMR at 1 month (Table 1). On the other hand patients with a significant reduction of EPC at 1 month post-HT compared with HT were less likely to have either ACR or AMR (p=0.0003). During longer post-HT observation (12 months) patients had similar EPC levels regardless of the rejection events. Dynamic changes in EPC levels are presented in figure. Nonetheless, greater changes in EPC expressed by coefficient of variation were associated with the risk of either AMR or ACR compared to the participants without rejection (mean [lower–upper quartile]) 15 [13–18] vs 8 [5–13]; p=0.02) and (22 [14–26] vs 8 [5–13]; p=0.01) respectively. EPC by rejection – 1st month following HT ACR (+) AMR (+) ACR (−) and AMR (−) p^ p p N=3 (mean± SD) N=4 (mean± SD) N=20 (mean± SD) ACR (+) vs ACR (−) and AMR (−) AMR (+) vs ACR (−) and AMR (−) EPC log HT 5.14±1.55 3.81±1.01 5.30±0.88 0.0325 0.97 0.025 EPC log M1 4.97±0.59 3.69±1.33 4.15±1.29 0.4160 0.55 0.78 Delta EPC log M1-HT -0.17±1.98* −0.12±1.30* −1.15±1.18# 0.2195 0.44 0.32 ACR – acute cellular rejection; AMR or – acute antibody-mediated rejection; EPC log – endothelial progenitor cells after logarithmic transformation; HT – within 24 hours post-transplantation; M1 – at 1-month post-transplantation; Delta EPC log M1-HT – difference in EPC log between M1 and HT. #p=0.0003 for the difference between M1 vs HT; *p=ns for the difference between M1 vs HT; ^pP – for the difference among the groups. Changes in EPC level post-HT Conclusions Early reduction of EPC levels was predictive of a lower risk of ACR or AMR. Greater dynamic changes
doi_str_mv 10.1093/eurheartj/ehz747.0352
format article
fullrecord <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_eurheartj_ehz747_0352</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/eurheartj/ehz747.0352</oup_id><sourcerecordid>10.1093/eurheartj/ehz747.0352</sourcerecordid><originalsourceid>FETCH-LOGICAL-c872-fd79625760124a8ffc4ed0436bff794e3d2162d961cada0b24b717128998fbbd3</originalsourceid><addsrcrecordid>eNqNkMtKxDAYhYMoOI4-gtAX6MyfNJdmKeMVBhSZhbuS5mI7xKYk6UKf3hkrrl2dzfnOgQ-hawwrDLJa2yl2VsW8X9vuS1CxgoqRE7TAjJBScspO0QKwZCXn9ds5ukhpDwA1x3yBbl8Eg9fgbRFcofuoJ69yP7wXdjAhd9b3yhfaep-KMaRc_hwVOaohjV4N-VAOwyU6c8one_WbS7S7v9ttHsvt88PT5mZb6lqQ0hkhOWGCAyZU1c5pag3QirfOCUltZQjmxEiOtTIKWkJbgQUmtZS1a1tTLRGbZ3UMKUXrmjH2Hyp-Nhiao4nmz0Qzm2iOJg4czFyYxn8i36fiZwk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>P750Role of circulating endothelial cells post-heart transplantation</title><source>Oxford Journals Online</source><creator>Rywik, T ; Braniewska, A ; Kowalik, I ; Firczuk, M ; Kozar-Kaminska, K ; Wojciechowska, A ; Kasprzyk-Pawelec, A ; Sobieszczanska-Malek, M ; Leszek, P ; Rozentryt, P ; Zielinski, T</creator><creatorcontrib>Rywik, T ; Braniewska, A ; Kowalik, I ; Firczuk, M ; Kozar-Kaminska, K ; Wojciechowska, A ; Kasprzyk-Pawelec, A ; Sobieszczanska-Malek, M ; Leszek, P ; Rozentryt, P ; Zielinski, T</creatorcontrib><description>Abstract Background The role of endothelial progenitor cells (EPC) in heart transplantation (HT) is not well defined. Thus, the aim of this study was to evaluate prospectively the dynamic changes of circulating EPC levels in relation to post-HT rejection risk. Methods There were 27 HT recipients who had EPC from peripheral blood quantified during 6 months follow-up after HT. Patients were monitored regularly, by right ventricular endomyocardial biopsy assessment, for cellular rejection (ACR) defined as grade ≥2 or an antibody-mediated rejection (AMR) characterized by histopathological changes recorded as AMR1H. The primary end-point was acute rejection, either AMR or ACR. Results ACR and AMR were observed in 7 (25.9%) and 6 (22.2%) subjects respectively. EPC levels, after logarithmic transformation, immediately post-HT were alike regardless of ACR status, however patients with lower EPC were at risk of AMR at 1 month (Table 1). On the other hand patients with a significant reduction of EPC at 1 month post-HT compared with HT were less likely to have either ACR or AMR (p=0.0003). During longer post-HT observation (12 months) patients had similar EPC levels regardless of the rejection events. Dynamic changes in EPC levels are presented in figure. Nonetheless, greater changes in EPC expressed by coefficient of variation were associated with the risk of either AMR or ACR compared to the participants without rejection (mean [lower–upper quartile]) 15 [13–18] vs 8 [5–13]; p=0.02) and (22 [14–26] vs 8 [5–13]; p=0.01) respectively. EPC by rejection – 1st month following HT ACR (+) AMR (+) ACR (−) and AMR (−) p^ p p N=3 (mean± SD) N=4 (mean± SD) N=20 (mean± SD) ACR (+) vs ACR (−) and AMR (−) AMR (+) vs ACR (−) and AMR (−) EPC log HT 5.14±1.55 3.81±1.01 5.30±0.88 0.0325 0.97 0.025 EPC log M1 4.97±0.59 3.69±1.33 4.15±1.29 0.4160 0.55 0.78 Delta EPC log M1-HT -0.17±1.98* −0.12±1.30* −1.15±1.18# 0.2195 0.44 0.32 ACR – acute cellular rejection; AMR or – acute antibody-mediated rejection; EPC log – endothelial progenitor cells after logarithmic transformation; HT – within 24 hours post-transplantation; M1 – at 1-month post-transplantation; Delta EPC log M1-HT – difference in EPC log between M1 and HT. #p=0.0003 for the difference between M1 vs HT; *p=ns for the difference between M1 vs HT; ^pP – for the difference among the groups. Changes in EPC level post-HT Conclusions Early reduction of EPC levels was predictive of a lower risk of ACR or AMR. Greater dynamic changes of EPC during 6 months of observation were associated with a higher risk of rejection suggesting an important role of EPC in the pathological processes post-HT. Thus our findings suggest significant role of EPC post-HT with respect to rejection status. Acknowledgement/Funding Intramural research grant from the Institute of Cardiology</description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/eurheartj/ehz747.0352</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>European heart journal, 2019-10, Vol.40 (Supplement_1)</ispartof><rights>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com. 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Rywik, T</creatorcontrib><creatorcontrib>Braniewska, A</creatorcontrib><creatorcontrib>Kowalik, I</creatorcontrib><creatorcontrib>Firczuk, M</creatorcontrib><creatorcontrib>Kozar-Kaminska, K</creatorcontrib><creatorcontrib>Wojciechowska, A</creatorcontrib><creatorcontrib>Kasprzyk-Pawelec, A</creatorcontrib><creatorcontrib>Sobieszczanska-Malek, M</creatorcontrib><creatorcontrib>Leszek, P</creatorcontrib><creatorcontrib>Rozentryt, P</creatorcontrib><creatorcontrib>Zielinski, T</creatorcontrib><title>P750Role of circulating endothelial cells post-heart transplantation</title><title>European heart journal</title><description>Abstract Background The role of endothelial progenitor cells (EPC) in heart transplantation (HT) is not well defined. Thus, the aim of this study was to evaluate prospectively the dynamic changes of circulating EPC levels in relation to post-HT rejection risk. Methods There were 27 HT recipients who had EPC from peripheral blood quantified during 6 months follow-up after HT. Patients were monitored regularly, by right ventricular endomyocardial biopsy assessment, for cellular rejection (ACR) defined as grade ≥2 or an antibody-mediated rejection (AMR) characterized by histopathological changes recorded as AMR1H. The primary end-point was acute rejection, either AMR or ACR. Results ACR and AMR were observed in 7 (25.9%) and 6 (22.2%) subjects respectively. EPC levels, after logarithmic transformation, immediately post-HT were alike regardless of ACR status, however patients with lower EPC were at risk of AMR at 1 month (Table 1). On the other hand patients with a significant reduction of EPC at 1 month post-HT compared with HT were less likely to have either ACR or AMR (p=0.0003). During longer post-HT observation (12 months) patients had similar EPC levels regardless of the rejection events. Dynamic changes in EPC levels are presented in figure. Nonetheless, greater changes in EPC expressed by coefficient of variation were associated with the risk of either AMR or ACR compared to the participants without rejection (mean [lower–upper quartile]) 15 [13–18] vs 8 [5–13]; p=0.02) and (22 [14–26] vs 8 [5–13]; p=0.01) respectively. EPC by rejection – 1st month following HT ACR (+) AMR (+) ACR (−) and AMR (−) p^ p p N=3 (mean± SD) N=4 (mean± SD) N=20 (mean± SD) ACR (+) vs ACR (−) and AMR (−) AMR (+) vs ACR (−) and AMR (−) EPC log HT 5.14±1.55 3.81±1.01 5.30±0.88 0.0325 0.97 0.025 EPC log M1 4.97±0.59 3.69±1.33 4.15±1.29 0.4160 0.55 0.78 Delta EPC log M1-HT -0.17±1.98* −0.12±1.30* −1.15±1.18# 0.2195 0.44 0.32 ACR – acute cellular rejection; AMR or – acute antibody-mediated rejection; EPC log – endothelial progenitor cells after logarithmic transformation; HT – within 24 hours post-transplantation; M1 – at 1-month post-transplantation; Delta EPC log M1-HT – difference in EPC log between M1 and HT. #p=0.0003 for the difference between M1 vs HT; *p=ns for the difference between M1 vs HT; ^pP – for the difference among the groups. Changes in EPC level post-HT Conclusions Early reduction of EPC levels was predictive of a lower risk of ACR or AMR. Greater dynamic changes of EPC during 6 months of observation were associated with a higher risk of rejection suggesting an important role of EPC in the pathological processes post-HT. Thus our findings suggest significant role of EPC post-HT with respect to rejection status. Acknowledgement/Funding Intramural research grant from the Institute of Cardiology</description><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqNkMtKxDAYhYMoOI4-gtAX6MyfNJdmKeMVBhSZhbuS5mI7xKYk6UKf3hkrrl2dzfnOgQ-hawwrDLJa2yl2VsW8X9vuS1CxgoqRE7TAjJBScspO0QKwZCXn9ds5ukhpDwA1x3yBbl8Eg9fgbRFcofuoJ69yP7wXdjAhd9b3yhfaep-KMaRc_hwVOaohjV4N-VAOwyU6c8one_WbS7S7v9ttHsvt88PT5mZb6lqQ0hkhOWGCAyZU1c5pag3QirfOCUltZQjmxEiOtTIKWkJbgQUmtZS1a1tTLRGbZ3UMKUXrmjH2Hyp-Nhiao4nmz0Qzm2iOJg4czFyYxn8i36fiZwk</recordid><startdate>20191001</startdate><enddate>20191001</enddate><creator>Rywik, T</creator><creator>Braniewska, A</creator><creator>Kowalik, I</creator><creator>Firczuk, M</creator><creator>Kozar-Kaminska, K</creator><creator>Wojciechowska, A</creator><creator>Kasprzyk-Pawelec, A</creator><creator>Sobieszczanska-Malek, M</creator><creator>Leszek, P</creator><creator>Rozentryt, P</creator><creator>Zielinski, T</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20191001</creationdate><title>P750Role of circulating endothelial cells post-heart transplantation</title><author>Rywik, T ; Braniewska, A ; Kowalik, I ; Firczuk, M ; Kozar-Kaminska, K ; Wojciechowska, A ; Kasprzyk-Pawelec, A ; Sobieszczanska-Malek, M ; Leszek, P ; Rozentryt, P ; Zielinski, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c872-fd79625760124a8ffc4ed0436bff794e3d2162d961cada0b24b717128998fbbd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rywik, T</creatorcontrib><creatorcontrib>Braniewska, A</creatorcontrib><creatorcontrib>Kowalik, I</creatorcontrib><creatorcontrib>Firczuk, M</creatorcontrib><creatorcontrib>Kozar-Kaminska, K</creatorcontrib><creatorcontrib>Wojciechowska, A</creatorcontrib><creatorcontrib>Kasprzyk-Pawelec, A</creatorcontrib><creatorcontrib>Sobieszczanska-Malek, M</creatorcontrib><creatorcontrib>Leszek, P</creatorcontrib><creatorcontrib>Rozentryt, P</creatorcontrib><creatorcontrib>Zielinski, T</creatorcontrib><collection>CrossRef</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rywik, T</au><au>Braniewska, A</au><au>Kowalik, I</au><au>Firczuk, M</au><au>Kozar-Kaminska, K</au><au>Wojciechowska, A</au><au>Kasprzyk-Pawelec, A</au><au>Sobieszczanska-Malek, M</au><au>Leszek, P</au><au>Rozentryt, P</au><au>Zielinski, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P750Role of circulating endothelial cells post-heart transplantation</atitle><jtitle>European heart journal</jtitle><date>2019-10-01</date><risdate>2019</risdate><volume>40</volume><issue>Supplement_1</issue><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract>Abstract Background The role of endothelial progenitor cells (EPC) in heart transplantation (HT) is not well defined. Thus, the aim of this study was to evaluate prospectively the dynamic changes of circulating EPC levels in relation to post-HT rejection risk. Methods There were 27 HT recipients who had EPC from peripheral blood quantified during 6 months follow-up after HT. Patients were monitored regularly, by right ventricular endomyocardial biopsy assessment, for cellular rejection (ACR) defined as grade ≥2 or an antibody-mediated rejection (AMR) characterized by histopathological changes recorded as AMR1H. The primary end-point was acute rejection, either AMR or ACR. Results ACR and AMR were observed in 7 (25.9%) and 6 (22.2%) subjects respectively. EPC levels, after logarithmic transformation, immediately post-HT were alike regardless of ACR status, however patients with lower EPC were at risk of AMR at 1 month (Table 1). On the other hand patients with a significant reduction of EPC at 1 month post-HT compared with HT were less likely to have either ACR or AMR (p=0.0003). During longer post-HT observation (12 months) patients had similar EPC levels regardless of the rejection events. Dynamic changes in EPC levels are presented in figure. Nonetheless, greater changes in EPC expressed by coefficient of variation were associated with the risk of either AMR or ACR compared to the participants without rejection (mean [lower–upper quartile]) 15 [13–18] vs 8 [5–13]; p=0.02) and (22 [14–26] vs 8 [5–13]; p=0.01) respectively. EPC by rejection – 1st month following HT ACR (+) AMR (+) ACR (−) and AMR (−) p^ p p N=3 (mean± SD) N=4 (mean± SD) N=20 (mean± SD) ACR (+) vs ACR (−) and AMR (−) AMR (+) vs ACR (−) and AMR (−) EPC log HT 5.14±1.55 3.81±1.01 5.30±0.88 0.0325 0.97 0.025 EPC log M1 4.97±0.59 3.69±1.33 4.15±1.29 0.4160 0.55 0.78 Delta EPC log M1-HT -0.17±1.98* −0.12±1.30* −1.15±1.18# 0.2195 0.44 0.32 ACR – acute cellular rejection; AMR or – acute antibody-mediated rejection; EPC log – endothelial progenitor cells after logarithmic transformation; HT – within 24 hours post-transplantation; M1 – at 1-month post-transplantation; Delta EPC log M1-HT – difference in EPC log between M1 and HT. #p=0.0003 for the difference between M1 vs HT; *p=ns for the difference between M1 vs HT; ^pP – for the difference among the groups. Changes in EPC level post-HT Conclusions Early reduction of EPC levels was predictive of a lower risk of ACR or AMR. Greater dynamic changes of EPC during 6 months of observation were associated with a higher risk of rejection suggesting an important role of EPC in the pathological processes post-HT. Thus our findings suggest significant role of EPC post-HT with respect to rejection status. Acknowledgement/Funding Intramural research grant from the Institute of Cardiology</abstract><pub>Oxford University Press</pub><doi>10.1093/eurheartj/ehz747.0352</doi></addata></record>
fulltext fulltext
identifier ISSN: 0195-668X
ispartof European heart journal, 2019-10, Vol.40 (Supplement_1)
issn 0195-668X
1522-9645
language eng
recordid cdi_crossref_primary_10_1093_eurheartj_ehz747_0352
source Oxford Journals Online
title P750Role of circulating endothelial cells post-heart transplantation
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T07%3A55%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P750Role%20of%20circulating%20endothelial%20cells%20post-heart%20transplantation&rft.jtitle=European%20heart%20journal&rft.au=Rywik,%20T&rft.date=2019-10-01&rft.volume=40&rft.issue=Supplement_1&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/eurheartj/ehz747.0352&rft_dat=%3Coup_cross%3E10.1093/eurheartj/ehz747.0352%3C/oup_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c872-fd79625760124a8ffc4ed0436bff794e3d2162d961cada0b24b717128998fbbd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/eurheartj/ehz747.0352&rfr_iscdi=true